Anti‐erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus
Jordan M. Schecter, J. Gregory Mears, Bachir Alobeid, Paul J. Gaglio – 29 October 2007 – After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues.